Priority Review News Today

i should pay them a visit. were hanging out on the couch with griff and rachel talking about all kinds of stuff. talking about if we should have christmas trees up, apparently theres some buses that people have been thrown under. i dont know. what do you think about it, griff? >> griff: well, im not even going to go into what i was accused of this idea of throwing anybody under the bus about you weve had this important debate whether you keep your tree up and of course were getting fee...

The sNDA is supported by data from the phase 3 LAURA trial.

/PRNewswire/ -- Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, announced the outcome of the U.S. Food and Drug...

03.06.2024 - MELBOURNE, Australia, June 03, 2024 (GLOBE NEWSWIRE) - Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and ... Seite 1

MELBOURNE, Australia, June 3, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application

ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination

BEIJING and SHANGHAI and CHICAGO, June 2, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets,

/PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor...

Preliminary analysis of data from the EPCORE NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in combination with rituximab-lenalidomide

02.06.2024 - Genmab A/S (Nasdaq: GMAB) today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of ...